These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
138 related items for PubMed ID: 8058709
1. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Bhargava V, Thor A, Deng G, Ljung BM, Moore DH, Waldman F, Benz C, Goodson W, Mayall B, Chew K. Mod Pathol; 1994 Apr; 7(3):361-8. PubMed ID: 8058709 [Abstract] [Full Text] [Related]
2. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Hurlimann J, Chaubert P, Benhattar J. Mod Pathol; 1994 May; 7(4):423-8. PubMed ID: 8066070 [Abstract] [Full Text] [Related]
3. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. O'Malley FP, Vnencak-Jones CL, Dupont WD, Parl F, Manning S, Page DL. Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120 [Abstract] [Full Text] [Related]
4. p53 mutations and histological type of invasive breast carcinoma. Marchetti A, Buttitta F, Pellegrini S, Campani D, Diella F, Cecchetti D, Callahan R, Bistocchi M. Cancer Res; 1993 Oct 01; 53(19):4665-9. PubMed ID: 8402644 [Abstract] [Full Text] [Related]
5. The role of p53 mutations in bilateral breast carcinoma. Ackerman J, Baunoch DA, Gimotty P, George J, Lane MA, Dawson PJ. Mod Pathol; 1995 Apr 01; 8(3):244-8. PubMed ID: 7617647 [Abstract] [Full Text] [Related]
6. Loss of heterozygosity and p53 gene mutations in breast cancer. Deng G, Chen LC, Schott DR, Thor A, Bhargava V, Ljung BM, Chew K, Smith HS. Cancer Res; 1994 Jan 15; 54(2):499-505. PubMed ID: 8275488 [Abstract] [Full Text] [Related]
7. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity. Shen KL, Yang LS, Hsieh HF, Chen CJ, Yu JC, Tsai NM, Harn HJ. J Surg Oncol; 2000 Jun 15; 74(2):100-7. PubMed ID: 10914818 [Abstract] [Full Text] [Related]
8. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women. Temmim L, Baker H, Sinowatz F. Anticancer Res; 2001 Jun 15; 21(1B):743-8. PubMed ID: 11299837 [Abstract] [Full Text] [Related]
9. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy. Turner BC, Gumbs AA, Carbone CJ, Carter D, Glazer PM, Haffty BG. Cancer; 2000 Mar 01; 88(5):1091-8. PubMed ID: 10699900 [Abstract] [Full Text] [Related]
10. p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Shao ZM, Wu J, Shen ZZ, Nguyen M. Clin Cancer Res; 2001 Aug 01; 7(8):2222-7. PubMed ID: 11489795 [Abstract] [Full Text] [Related]
11. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P. Breast J; 2005 Aug 01; 11(4):278-80. PubMed ID: 15982396 [Abstract] [Full Text] [Related]
12. [Comparison of nuclear accumulation of p53 protein with mutations in the p53 gene on the tissues of human breast cancer]. Fan P, Wu Z, Cha X, Wang X, Wang S. Zhonghua Wai Ke Za Zhi; 1998 Nov 01; 36(11):655-7. PubMed ID: 11825490 [Abstract] [Full Text] [Related]
13. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Fernö M, Parwaresch R, Alm P. J Pathol; 1999 Jan 01; 187(2):207-16. PubMed ID: 10365096 [Abstract] [Full Text] [Related]
14. Interest of investigating p53 status in breast cancer by four different methods. Thirion A, Rouanet P, Thezenas S, Detournay D, Grenier J, Lopez-Crapez E. Oncol Rep; 2002 Jan 01; 9(6):1167-72. PubMed ID: 12375013 [Abstract] [Full Text] [Related]
15. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S. J Am Coll Surg; 2004 Jan 01; 198(1):83-90. PubMed ID: 14698315 [Abstract] [Full Text] [Related]
16. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Elledge RM, Clark GM, Fuqua SA, Yu YY, Allred DC. Cancer Res; 1994 Jul 15; 54(14):3752-7. PubMed ID: 8033095 [Abstract] [Full Text] [Related]
17. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Krajewski S, Thor AD, Edgerton SM, Moore DH, Krajewska M, Reed JC. Clin Cancer Res; 1997 Feb 15; 3(2):199-208. PubMed ID: 9815673 [Abstract] [Full Text] [Related]
18. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer. Eissa S, Khalifa A, el-Gharib A, Salah N, Mohamed MK. Anticancer Res; 1997 Feb 15; 17(2B):1417-23. PubMed ID: 9137508 [Abstract] [Full Text] [Related]
19. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH. Mod Pathol; 2002 Aug 15; 15(8):853-61. PubMed ID: 12181271 [Abstract] [Full Text] [Related]
20. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Liu S, Edgerton SM, Moore DH, Thor AD. Clin Cancer Res; 2001 Jun 15; 7(6):1716-23. PubMed ID: 11410511 [Abstract] [Full Text] [Related] Page: [Next] [New Search]